Novel Drug Delivery Systems (NDDS) Market Is Predicted To Surge At A CAGR Of 6.6% By 2027

Worldwide demand for novel drug delivery systems (NDDS) is predicted to surge at a CAGR of 6.6% from 2022 to 2027. At present, the global novel drug delivery systems market enjoys a valuation of US$ 62.5 billion and is anticipated to climb to a market size of US$ 86 billion by the end of 2027. Oral drug delivery systems are projected to be extremely popular over the coming years owing to their ease of administration and the increasing patient-centric approach of the healthcare sector.

The offer in this portion accompanies many open doors including fabricating items, appropriation, retail, and showcasing administrations. Broad rounds of essential and far reaching optional exploration have been utilized by the examiners at Fact.MR to show up at different assessments and projections for Demand of Novel Drug Delivery Systems (NDDS) Market both at worldwide and provincial levels.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗖𝗼𝗽𝘆 𝗼𝗳 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁: -https://www.factmr.com/connectus/sample?flag=S&rep_id=7604?PJ

𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: -

AstraZeneca PLC
Boston Scientific
Genzyme Co.
Bayer AG
Novartis AG
Pfizer Inc.
Sanofi SA
Tolmar
GlaxoSmithKline PLC
Johnson & Johnson
Astellas
Aspen
Lupin
Breckenridge Pharmaceuticals
Shire
Galen
3M Company
Merck & Co. Inc.
Teva Pharmaceuticals Industries Limited
Abbott Laboratories

𝗥𝗲𝗰𝗲𝗻𝘁 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗡𝗲𝘄𝘀

Johnson & Johnson's Investment in Lipid Nanoparticle Technology: Johnson & Johnson recently announced a substantial investment in lipid nanoparticle technology, with the aim of enhancing its drug delivery capabilities. This technology is particularly crucial for the efficient delivery of RNA-based therapeutics, such as mRNA vaccines and gene therapies.

Roche's Collaboration for Targeted Drug Delivery: Roche entered into a collaboration with a specialized drug delivery company to develop targeted drug delivery systems. This partnership aims to improve the effectiveness of cancer therapies by precisely delivering drugs to tumor sites, minimizing collateral damage to healthy tissue.

Pfizer's Development of Microneedle Patches: Pfizer has been working on the development of microneedle patches for the delivery of vaccines and medications. These painless, patch-based delivery systems have the potential to revolutionize drug administration, especially in pediatric and geriatric populations.

GlaxoSmithKline's Advancements in Inhalation Drug Delivery: GlaxoSmithKline has made significant progress in the development of advanced inhalation drug delivery systems. These systems are crucial for respiratory treatments and offer improved precision and patient compliance.

Novartis's Focus on Biodegradable Nanoparticles: Novartis has been actively researching and developing biodegradable nanoparticles for drug delivery. This environmentally friendly approach is aligned with the growing emphasis on sustainability and responsible healthcare practices.

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

Key companies in the novel drug delivery systems market are expected to bolster their focus on the launch of new and modern drug delivery systems equipped with advanced technologies.

In June 2022, Gulfic Biosciences Ltd., an innovative pharmaceutical company, announced the launch of a new drug delivery system. The new drug delivery system technology was developed by Gulfic and its French counterpart at an affordable price. The new system is called Dual Chamber Bags (DCB).

In May 2022, Jabil Healthcare, a leading name in the healthcare industry, announced the launch of a reusable drug delivery device with a broader spectrum of applications. The Qfinity Autoinjector Platform will be available at lower costs than its market alternatives and is expected to further bolster the sustainability trend in the drug delivery industry owing to its reusable nature.

NDDS market players are also expected to eye acquisitions, partnerships, and mergers to enhance their business scope and expand their market presence across the world.

Bayer, a German biotechnology and pharmaceutical organization, in August 2021, announced the acquisition of Vividion Therapeutics to strengthen its portfolio of novel drug discovery platforms. The acquisition was valued at US$ 1.5 billion.

In June 2022, Accord Biopharma and EVERSANA partnered to launch the CAMCEVI (leuprolide) 42mg injection emulsion that is expected to be used for the treatment of prostate cancer in adults.

𝗞𝗲𝘆 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀 𝗼𝗳 𝗡𝗗𝗗𝗦 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵

𝗕𝘆 𝗥𝗼𝘂𝘁𝗲:
Oral Drug Delivery Systems
Injectable Drug Delivery Systems
Pulmonary Drug Delivery Systems
Transdermal Drug Delivery Systems
Others

𝗕𝘆 𝗠𝗼𝗱𝗲 :
Targeted Drug Delivery Systems
Controlled Drug Delivery Systems
Modulated Drug Delivery Systems

𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀

The NDDS market faces both challenges and opportunities. Challenges include the need for robust research and development efforts to design efficient drug delivery systems, the high costs associated with developing and manufacturing novel systems, and the regulatory hurdles that come with introducing new drug delivery technologies.

Opportunities in the market include the potential for personalized medicine and the delivery of targeted therapies that reduce side effects and improve patient outcomes. Additionally, the expanding use of nanotechnology in drug delivery opens doors to delivering a broader range of therapeutics more effectively. Furthermore, innovations in patient-friendly drug delivery, such as wearable devices and smart injectors, offer new avenues for market growth.

𝗚𝗲𝘁 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝘁𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀:https://www.factmr.com/connectus/sample?flag=RC&rep_id=7604?PJ

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.